Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...
GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company
GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product...
China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products
The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...
Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...
Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC
Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s...
Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...
BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced...
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...
Novo Nordisk’s Alhemo Receives CHMP Recommendation for Haemophilia Prophylaxis in Europe
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has been notified that the Committee for...
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD...
Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...
Kanghong Pharmaceutical’s NASH Drug KH629 Approved for Clinical Trials in China
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Huadong Medicine Gets Green Light for HPK1 PROTAC Drug HDM2006 in Advanced Solid Tumors
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding...
Astellas Pharma’s Vyloy Receives FDA Approval for Gastric Cancer Treatment in CLDN18.2 Positive Tumors
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has announced that it has received...
Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma
Gilead Sciences Inc., (NASDAQ: GILD), a leading US-based biopharmaceutical company, has announced its intention to...
Jiangsu Hengrui Pharmaceuticals Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MicroPort Sorim CRM’s PLATINIUM Series ICD Receives NMPA Approval, A First for China
MicroPort Sorim CRM, a Chinese medical device company, has announced that it has received market...
Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced that it has received Orphan...